Search API
Earlier in 2024, countries and partners committed nearly $600 million in new funding towards elimination of cervical cancer. About 95% of the 660,000 cervical cancer cases occurring globally each year are caused by the human papillomavirus (HPV).
To expand access to HPV vaccines, the World Health Organization (WHO) announced that a fourth WHO-prequalified vaccine, Cecolin®, has been confirmed for use in a single-dose schedule.
A growing number of HPV vaccine products initially prequalified for use in a 2-dose schedule can now be used in a single-dose schedule.
“Unlike most other cancers, we can eliminate cervical cancer, along with its painful inequities,” said Dr. Tedros Adhanom Ghebreyesus, WHO Director-General, in a press release on October 4, 2024.
“By adding another option for a one-dose HPV vaccination schedule, we have taken another step closer to consigning cervical cancer to history.”
The WHO also confirmed an additional HPV vaccine, Walrinvax®, is now the fifth product available on the global market. Walrinvax® is prequalified with a two-dose schedule. Further data will be needed to assess if this vaccine can be recommended for single-dose schedules in the future, says the WHO.
Based on the Ministry of Health guidelines, the Republic of Rwanda's Development Board provided the following update on Marburg Virus Disease (MVD).
This viral hemorrhagic fever has claimed 12 lives from 41 cases over the past month.
As of October 4, 2024, no travel restrictions are currently in place, and all key tourist destinations, including Volcanoes National Park, Akagera National Park, Gishwati Mukura National Park, and Nyungwe National Park, are fully operational.
However, at points of entry, visitors should expect routine temperature checks and the provision of hand sanitizing stations at airports and other border crossings.
All people exiting Rwanda will undergo an MVD symptom screening questionnaire to ensure their well-being and the safety of others.
And tourists to this African country are advised to remain vigilant and practice good personal hygiene, such as avoiding close contact with individuals displaying symptoms such as high fever or severe headaches.
The U.S. CDC published an updated travel advisory on October 3, 2024, highlighting actions to prevent contracting MVD while visiting Rwanda.
As of today, no approved MVD vaccines are available.
According to a research letter published in the Journal of the American Medical Association (JAMA), Bavarian Nordic’s mpox vaccine JYNNEOS® (MVA-BN®) protection appears to weaken within six to 12 months after injection.
Two doses provided 66% effectiveness, and one dose provided 36% effectiveness at peak immunity during the 2022 clade 2 mpox outbreak.
This finding raises questions about whether the two-dose vaccine may been 'booster' shots to confer lasting protection against the mpox virus.
However, the U.S. CDC wrote on September 12, 2024, 'Right now, getting more than two mpox vaccine doses (a "booster") isn't recommended.'
“Our data suggest that protective immunity may be waning in individuals who were vaccinated with this vaccine in 2022,” corresponding author Dan Barouch said in a related statement on October 3, 2024.
On September 26, 2024, Bavarian Nordic announced an agreement with UNICEF to supply 1 million doses of the MVA-BN® mpox / smallpox vaccine for African countries confronting the clade 1 mpox outbreak.
In the United States, JYNNEOS is now commercially available at clinics and pharmacies.
The U.S. Centers for Disease Control and Prevention (CDC) confirmed last month that respiratory syncytial virus (RSV) is the most common cause of hospitalization among U.S. infants.
Since last year, when Beyfortus™ became the first U.S. FDA-approved single-dose, extended half-life monoclonal antibody (mAb) offering passive immunization to prevent lower respiratory tract infections caused by RSV, numerous researchers have focused on determining its real-world effectiveness.
The CDC has clarified that mAbs are not vaccines but offer disease protection.
According to a study's results published by The Lance in October 2024 (Volume 8, Issue 10p721-729), Beyfortus's estimated effectiveness against RSV-associated hospitalizations for bronchiolitis was 73% (61–84), corresponding to one hospitalization averted for every 39 (26–54) doses administered.
And in sensitivity analyses, nirsevimab remained effective against RSV-associated hospitalizations for bronchiolitis after emergency department attendance.
As of October 4, 2024, there is ample supply of Beyforus in the U.S., well ahead of the 2024-2025 RSV season's peak, expected in December or January.
The Los Angeles County Department of Public Health confirmed today that locally acquired Dengue is emerging, which is extremely rare in a region where mosquitoes have not previously transmitted the virus.
LA is investigating a new case of locally acquired Dengue in an El Monte resident.
This case of local transmission is the fifth case of locally acquired Dengue reported in LA County's San Gabriel Valley (2 million population) this year.
Similar to the cases reported in Baldwin Park (3) and Panorama City (1), this person had no history of travel to areas where Dengue is endemic.
“This case further indicates that Dengue can spread in our community. Preventing mosquito bites and breeding is the best way to stop local dengue transmission,” said Muntu Davis, MD, MPH, Los Angeles County Health Officer, in a press release on October 3, 2024.
On the U.S. southeast coast, the state of Florida reported 548 travel-associated and 40 locally acquired dengue cases in 2024.
Throughout the Region of the Americas, over 11 million Dengue cases and 6,700 related fatalities have been confirmed in the Americas this year.
While Dengue is a vaccine-preventable disease, no vaccine is currently available in the U.S.
The World Health Organization (WHO) reported today that West Nile Virus (WNV) had been detected in a child from Bagatelle, a parish in St. Thomas, located in Barbados, an island country in the Caribbean Sea.
On October 3, 2024, the WHO's Disease Outbreak News stated that this was the first human case of WNV detected in Barbados, which has a population of about 280,000.
Additionally, thousands of people visit Barbados yearly as it is a favorite vaccination destination and cruise ship port.
Additionally, no infections have been previously documented in birds or horses in Barbados, making this case both unusual and unexpected, wrote the WHO. Although no cases of WNV have been documented in birds or horses in the country, the virus may be circulating in these populations undetected.
However, the WNV has previously spread throughout the Caribbean, likely via infected migratory birds.
The WHO's risk of international dissemination of WNV from Barbados is low, as the virus is primarily transmitted through mosquito bites, with birds as the natural hosts.
Based on available information on this event, WHO does not recommend any restrictions on travel and/or trade for Barbados and will continue to evaluate the epidemiological situation in Barbados.
In the United States, 46 states have reported over 1,400 WNV cases in 2024.
From a prevention perspective, no approved West Nile virus vaccines are available for people in 2024.
According to Reuters, Gilead Sciences today announced it would donate about 5,000 vials of its antiviral drug remdesivir (Veklury®) for emergency use in response to the ongoing Marburg virus disease (MVD) outbreak in the Republic of Rwanda.
This U.S. FDA-approved antiviral drug is being evaluated since no approved MVD vaccines are available.
However, several Marburg vaccine candidates, utilizing various technologies, are actively conducting clinical trials.
The drugmaker clarified that Remdesivir, originally developed to treat Ebola, is not approved for treating Marburg disease anywhere, and its safety and efficacy against the virus is unknown.
As of October 3, 2024, Rwanad's first MVD outbreak has produced eleven fatalities out of 36 confirmed cases.
The World Helath Organization recently assessed the risk of this MVD outbreak as very high at the national level, high at the regional level, and low at the global level. And the local government anticipates additional MVD cases to be reported this year.
The Republic of Rwanda Ministry of Health posted on X that the death toll from the recent Marburg virus disease (MVD) outbreak has reached eleven out of 36 confirmed cases.
As of October 2, 2024, about 26 additional people are in isolation from this rare viral hemorrhagic fever in Kigali, the capital city of Rwanda, which has a population exceeding 1.7 million.
As of September 30, 2024, the World Helath Organization (WHO) assessed the risk of this MVD outbreak as very high at the national level, high at the regional level, and low at the global level.
The WHO says the source of this MVD outbreak, geographical extent, likely onset date, and additional epidemiological information on cases are still pending further investigation. Rwanda declared its initial MVD outbreak on September 27, 2024.
According to the AP, Rwandan Health Minister Sabin Nsanzimana said that vaccine clinical trials would start “within days” but failed to clarify which type of vaccine will be used.
As of October 3, 2024, various Marburg vaccine candidates are conducting studies. For example:
Public Health Vaccines, LLC launched its Phase 1 clinical trial in March 2024, evaluating its single-dose vaccine candidate, PHV01 (rVSV∆G-MARV-GP [Angola]).
On April 15, 2024, the U.S. FDA granted orphan drug designation to the active ingredient in MarVax™, the subunit protein vaccine of recombinantly expressed MARV glycoprotein, for "the prevention and post-exposure prophylaxis against MARV infection.
The U.S. CDC's recent travel advisory remains in effect, which states If you travel to the Republic of Rwanda, you should:
Avoid contact with sick people with fever, muscle pain, and rash symptoms.
Avoid contact with blood and other body fluids.
Avoid visiting healthcare facilities in the outbreak area for nonurgent medical care or for non-medical reasons.
